142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

Quality of Life Measures for Children with Sever's Disease - Why Agressive Treatment Is Important

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Tuesday, November 18, 2014 : 10:50 AM - 11:10 AM

Patrick DeHeer, DPM , Hooiser Foot and Ankle, Carmel, IN
The quality of life assoicated with symptomatic Sever's disease shows without doubt that these patients are affected in a negative manner and thus early and comprehensive treatment is required. The study done on this topic will be reviewed and then a review of the Sever's disease will be discussed. Finally, a comprehensive evidence-based treatment plan will be discussed. This will allow the attendee to diagnosis Sever's disease based on history and clinical findings, then provide a sound treatment plan to allow the patient to resume full activity without restrictions.

Learning Areas:

Implementation of health education strategies, interventions and programs
Other professions or practice related to public health
Public health or related research

Learning Objectives:
Analyze the quality of life changes that occur with Sever's disease. These negative changes in quality of life demonstrate the need for comprehensive and early treatment through resolution of symptoms to allow the patient to continue their prior activity levels thereby positively affecting quality of life. The evidence-based comprehensive treatment plan discussed will provide a clear directive for patient care.

Keyword(s): Quality of Life, Child Health

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a board certified Podiatric physician in private practice for 23 years. I have written and lecture on the topic at national meetings. I have served as guest editor for two recent books/journals based entirely on pediatrics.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.